Richard A. Heyman Sells 2,825 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 2,825 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $77,715.75. Following the transaction, the director now directly owns 125,760 shares of the company’s stock, valued at approximately $3,459,657.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Enliven Therapeutics Stock Performance

ELVN traded up $0.56 on Tuesday, reaching $28.01. 174,035 shares of the company’s stock were exchanged, compared to its average volume of 261,678. The company’s 50 day moving average is $23.26 and its 200-day moving average is $22.15. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -14.51 and a beta of 1.10. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $28.51.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of research analyst reports. Robert W. Baird initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective for the company. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC boosted its holdings in Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after buying an additional 3,189 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after buying an additional 8,540 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Enliven Therapeutics during the 1st quarter valued at approximately $167,000. Finally, SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $256,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.